Trade-Ideas LLC identified

Omeros

(

OMER

) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Omeros as such a stock due to the following factors:

  • OMER has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $10.3 million.
  • OMER has traded 133,095 shares today.
  • OMER is trading at 2.80 times the normal volume for the stock at this time of day.
  • OMER is trading at a new high 3.05% above yesterday's close.

'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in OMER with the Ticky from Trade-Ideas. See the FREE profile for OMER NOW at Trade-Ideas

More details on OMER:

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. Currently there are 6 analysts that rate Omeros a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for Omeros has been 423,100 shares per day over the past 30 days. Omeros has a market cap of $493.2 million and is part of the health care sector and drugs industry. The stock has a beta of 2.95 and a short float of 26.5% with 13.35 days to cover. Shares are down 4.2% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Omeros as a

sell

. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself.

Highlights from the ratings report include:

  • OMER's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 50.31%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • OMEROS CORP has improved earnings per share by 14.8% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past year. We feel that this trend should continue. This trend suggests that the performance of the business is improving. During the past fiscal year, OMEROS CORP continued to lose money by earning -$2.00 versus -$2.22 in the prior year. This year, the market expects an improvement in earnings (-$1.04 versus -$2.00).
  • The net income growth from the same quarter one year ago has exceeded that of the S&P 500 and greatly outperformed compared to the Pharmaceuticals industry average. The net income increased by 4.3% when compared to the same quarter one year prior, going from -$20.71 million to -$19.83 million.
  • OMER's very impressive revenue growth greatly exceeded the industry average of 2.7%. Since the same quarter one year prior, revenues leaped by 3608.3%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.